ScholarIQanswers from OpenAlex
Visterra (United States)
InstitutionResearch output, impact & collaborations
Visterra (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Visterra (United States)?
ScholarIQrecord summary
Visterra (United States) is a research organisation in Cambridge, US. OpenAlex records 85 works and 9,545 citations for it.
How many works does Visterra (United States) have?
ScholarIQindexed works
Visterra (United States) has 85 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Visterra (United States) have?
ScholarIQcitation count
Visterra (United States) has 9,545 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Visterra (United States)?
ScholarIQavg h-index
Visterra (United States) has an average h-index of 18 in OpenAlex.
What is the ROR of Visterra (United States)?
ScholarIQror
The ROR for Visterra (United States) is on the source record.
What is the OpenAlex record for Visterra (United States)?
ScholarIQopenalex
The OpenAlex for Visterra (United States) is on the source record.
Who are the most-cited researchers behind Visterra (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Visterra (United States)?
ScholarIQmost cited works
Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential
Louise A. Koopman, Hernan D. Kopcow, Basya Rybalov, Jonathan E. Boyson, Jordan S. Orange, Frederick Schatz, Rachel Masch, Charles J. Lockwood, Asher D. Schachter, Peter J. Park, Jack L. Strominger
Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible
Bernward Hinkes, Roger C. Wiggins, Rasheed Gbadegesin, Christopher N. Vlangos, Dominik Seelow, Gudrun Nürnberg, Puneet Garg, Rakesh Verma, Hassan Chaı̈b, Bethan E. Hoskins, Shazia Ashraf, Christian Becker, Hans Christian Hennies, Meera Goyal, Bryan L. Wharram, Asher D. Schachter, Sudha Mudumana, Iain A. Drummond, Dontscho Kerjaschki, Rüdiger Waldherr, Alexander Dietrich, Fatih Özaltın, Ayşı̇n Bakkaloğlu, Roxana Cleper, Lina Basel‐Vanagaite, Martin Pöhl, Martin Griebel, А.Н. Цыгин, Alper Soylu, Dominik Müller, Caroline S Sorli, Tom D. Bunney, Matilda Katan, Jinhong Liu, Massimo Attanasio, John F. O’Toole, K Hasselbacher, Bettina E. Mucha, Edgar A. Otto, Rannar Airik, Andreas Kispert, Grant G. Kelley, Alan V. Smrcka, Thomas Gudermann, Lawrence B. Holzman, Peter Nürnberg, Friedhelm Hildebrandt
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
Hiroyasu Tsukaguchi, Akulapalli Sudhakar, Tu C. Le, Nguyễn Thu Trang, Jun Yao, Joshua A. Schwimmer, Asher D. Schachter, Esteban Poch, Patrícia Ferreira Abreu, Gerald B. Appel, Aparecido B. Pereira, Raghu Kalluri, Martin R. Pollak
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mohit Mathur, Jonathan Barratt, Bobby Chacko, Tak Mao Chan, Laura Kooienga, Kook‐Hwan Oh, Manisha Sahay, Yusuke Suzuki, Muh Geot Wong, Jill Yarbrough, Jing Xia, Brian J.G. Pereira
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
Hiroyasu Tsukaguchi, Akulapalli Sudhakar, Tu C. Le, Nguyễn Thu Trang, Jun Yao, Joshua A. Schwimmer, Asher D. Schachter, Esteban Poch, Patrícia Ferreira Abreu, Gerald B. Appel, Aparecido B. Pereira, Raghu Kalluri, Martin R. Pollak
How much of the research on Visterra (United States) is open access?
ScholarIQopen access share
92%OPEN ACCESS